Cancer therapy: Targeting mitochondria and other sub-cellular organelles

Obinna C. Ubah, Heather M. Wallace

Research output: Contribution to journalArticlepeer-review

53 Citations (Scopus)


Tumour cell death is required for the clearance of malignant cells and is a vital part of the mechanism of natural tumour suppression. Cancer cells, having acquired multiple deregulated pathways involving several cellular oragenelles, are capable of disrupting these normally finely tuned processes thereby evading both physiological and therapeutic intervention. Although current available data indicate the dependence of successful tumour cell clearance on classical apoptotic pathways (intrinsic and/or extrinsic pathways), there is now evidence suggesting that alternative apoptotic and non-apoptotic pathways may effectively contribute to tumour cell death. The mitochondria, proteasomes, endoplasmic reticulum, Golgi apparatus, lysosomes and lysosome-related organelles of tumour cells exhibit a number of deregulations which have been identified as potential druggable targets for successful rational drug design and therapy. In this review, we summarise the roles of these cellular organelles in tumour initiation and establishment as well as current trends in development of agents that target deregulations in these organelles.

Original languageEnglish
Pages (from-to)201-222
Number of pages22
JournalCurrent Pharmaceutical Design
Issue number2
Publication statusPublished - 2014


  • Apoptosis
  • Cancer therapy
  • Endoplasmic reticulum
  • Golgi apparatus
  • Lysosome
  • MOMP
  • Polyamines
  • Proteasome
  • ROS
  • Warburg effect


Dive into the research topics of 'Cancer therapy: Targeting mitochondria and other sub-cellular organelles'. Together they form a unique fingerprint.

Cite this